CHRNA2 Gene Sequencing: Nocturnal Frontal Lobe Epilepsy Type 4 – Genetic Test in UAE

Executive Summary & Core Metrics

Executive Summary

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139) covering all coding and deep intronic regions of the CHRNA2 gene.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM for standard peripheral whole blood or extracted DNA specimens.
Clinical Guidance: Complimentary telephonic post‑test consultation to discuss variant interpretation, inheritance patterns, and implications for first‑degree relatives.
Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

This advanced molecular diagnostic test employs next‑generation sequencing (NGS) to analyse the entire coding sequence and flanking intronic boundaries of the CHRNA2 gene on chromosome 8p21.2. Pathogenic variants in CHRNA2 are associated with autosomal dominant nocturnal frontal lobe epilepsy type 4 (ENFL4), a condition characterised by clusters of brief, motor seizures occurring predominantly during non‑REM sleep. The test provides a definitive molecular diagnosis to guide targeted antiepileptic therapy, genetic counselling, and long‑term neurological surveillance.

Feature	Our Test – NGS Full Gene Sequencing	Closest Alternative – Single‑Gene Sanger
Precision	99.9% sensitivity; covers all coding exons, splice sites, and deep intronic regions >20 bp from exon boundaries	>99% but restricted to targeted hotspot codons; may miss novel or rare variants
Methodology	NGS with transcript‑aware alignment (Illumina platform); mean depth 150×; Q30 > 90%	Sanger dideoxy sequencing; low throughput; not suitable for mosaic detection
Turnaround Time	3–4 weeks	4–6 weeks
Regulatory Alignment	UAE PDPL (Federal Decree‑Law No. 45 of 2021) & Federal Law No. 2 of 2019 on health ICT	May not satisfy current genetic governance requirements for informed consent and data handling

Physician Insight & Safety Protocols

"CHRNA2 sequencing delivers high‑confidence molecular confirmation of autosomal dominant nocturnal frontal lobe epilepsy type 4 when integrated with seizure semiology and EEG data. The identified variant must be assessed within a three‑generation pedigree to provide accurate recurrence risk counselling and to guide family‑specific management strategies."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Medication Continuity Advisory

All prescribed antiepileptic drugs must be continued without interruption during and after the testing period. Do not alter or discontinue any medication regimen without direct authorisation from your treating neurologist, even after receiving genetic results.

Patient Safety Exclusion Criteria & Emergency Indicators

Exclusion: Individuals unable to provide informed consent for genetic testing must be accompanied by a legal guardian; pre‑test genetic counselling is mandatory per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Exclusion: Samples exhibiting haemolysis, insufficient DNA yield (<1 µg), or degraded nucleic acid will require recollection at no additional phlebotomy cost.
Emergency: A prolonged seizure lasting more than five minutes or repeated seizures without recovery between episodes requires immediate emergency medical attention — do not delay care awaiting genetic results.
Emergency: Sudden onset of confusion, unsteadiness, or respiratory difficulty during the sample collection or shipping window — proceed to the nearest emergency department.

Patient FAQ & Clinical Guidance

1. What is CHRNA2 gene sequencing and how does it confirm nocturnal frontal lobe epilepsy type 4?

CHRNA2 gene sequencing analyses the coding and regulatory regions of the gene encoding the alpha‑2 subunit of the neuronal nicotinic acetylcholine receptor. Pathogenic variants in this gene are linked to autosomal dominant nocturnal frontal lobe epilepsy type 4. The test provides a definitive molecular diagnosis with 99.9% accuracy, enabling precise prognosis, targeted therapy selection, and recurrence risk counselling for family members.

2. How is the sample collected for this genetic test and what preparation is required?

A standard peripheral whole blood sample (3–5 mL in EDTA) is collected by a trained phlebotomist. No special dietary preparation or medication withdrawal is needed. The sample is transported via temperature‑controlled cold‑chain logistics to the ISO 9001:2015 accredited laboratory. Alternatively, extracted DNA (≥1 µg) or a dried blood spot on an FTA card may be accepted if shipped under ambient conditions with appropriate desiccant.

3. What does a positive CHRNA2 variant mean for my family members and future children?

A pathogenic CHRNA2 variant carries a 50% recurrence risk for each offspring due to its autosomal dominant inheritance pattern. Predictive testing for at‑risk adult relatives is available after pre‑test genetic counselling. For family planning, preimplantation genetic testing and prenatal diagnosis options can be discussed with a consultant medical geneticist. Penetrance is incomplete, meaning not all variant carriers will manifest seizures, necessitating careful clinical correlation.

4. Can I receive my results via telemedicine and what follow‑up is provided?

Yes, results are disclosed during a dedicated telephonic or virtual consultation with a genetic counsellor or the referring neurologist. The session covers variant classification according to ACMG/AMP guidelines, clinical implications, medication optimisation strategies, and a personalised surveillance plan. A written clinical report is also provided for your medical records.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework

Personal Data Protection: All patient genetic data is processed and stored in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL). Data is encrypted at rest and in transit; access is restricted to authorised clinical personnel only.
Health Information Governance: The laboratory operates under Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health record management and audit‑trail integrity.
Medical Liability & Informed Consent: Pre‑test genetic counselling and written informed consent follow the standards of Federal Decree‑Law No. 4 of 2016 on Medical Liability, guaranteeing patient autonomy and comprehension of test implications.
Quality Certification: DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), reflecting commitment to rigorous quality management in all laboratory processes.

Clinical & Logistical Metadata

Test Name	CHRNA2 Gene Sequencing – Nocturnal Frontal Lobe Epilepsy Type 4 (ENFL4)
Price (AED)	2,800 AED
Turnaround Time	21–28 Business Days (3–4 Weeks)
Sample Type / Matrix	Whole Blood (3–5 mL EDTA), Extracted DNA (≥1 µg), or FTA Card Dried Blood Spot
Methodology Used	Next‑Generation Sequencing (NGS) – Full Gene Coverage incl. Coding Exons, Splice Sites, and Deep Intronic Regions, Mean Depth 150×
ICD-10-CM Code	G40.0, G40.809
LOINC Code	98557-8
DHA Facility License & Laboratory Address	DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE